Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples